Join with us to improve lives
PhotoPharmics traces its origins to the pioneering work of Apollo Light Systems, a company focused on the therapeutic potential of precisely delivered light. Apollo advanced early photobiomodulation technology and was ultimately acquired by Respironics, later part of Philips—bringing light-based medical innovation into the mainstream of regulated device development.
Building on that legacy, PhotoPharmics was formed to translate light science into a clinically rigorous, prescription-based platform targeting neurodegenerative disease. The company refined a non-invasive approach designed to stimulate specific neural networks implicated in Parkinson’s disease, its lead indication.
Clinical development progressed through Phase 2 studies that generated signals across motor and non-motor domains, helping shape the design of a fully powered Phase 3 pivotal trial. The program received FDA Breakthrough Device designation, reflecting both the unmet need in Parkinson’s and the potential of photo-neuromodulation as a novel therapeutic category.
With Celeste® as its lead program, PhotoPharmics has aligned its strategy around prescription-based DME distribution, positioning the technology as a regulated medical device rather than a consumer wellness product.
Today, PhotoPharmics is advancing a pivotal-stage platform in non-invasive photo-neuromodulation—beginning with Parkinson’s disease and expanding toward broader neurologic applications.
A Brief Overview
Lead Investigator, Ray Dorsey, MD, MBA
PhotoPharmics Founded
Founded following the sale of Apollo Light Systems to Philips/Respironics, establishing the foundation for next-generation neurological light therapy innovation.
First Patents Issued
Core intellectual property secured, protecting proprietary wavelength modulation and neurological targeting methods.
Celeste Human Trials Begin
Initial feasibility trials completed and Phase 2 clinical study initiated.
FDA De Novo Classification
De novo classification granted following Phase 2 completion with near statistical significance.
Breakthrough Device Designation
FDA Breakthrough Device designation granted, accelerating regulatory collaboration.
Pivotal Trial Underway
Large-scale pivotal trial underway to support regulatory submission and commercialization pathway.
Leadership Team
We are dedicated to improving the lives of those suffering from neurodegenerative diseases. We solve problems with rigorous science and innovative therapies. We have assembled a team with deep scientific, clinical, commercial, and leadership experience and expertise in medical technology and neurodegenerative diseases.
Kent Savage
CEO, Co-Founder
Former President and CEO at Apollo Light Systems where he led efforts to innovate, patent and deliver therapeutic light devices for mood and sleep disorders to more than 300,000 patients (sold to Philips Respironics).
Dan Adams
Science Officer, Co-Founder
At the forefront of research in circadian regulation and light therapy advances. 25+ years of commercial neuroscience and medical device experience. Former head of research for Apollo Light Systems and senior scientist for Philips.
Karl Kieburtz, MD, MPH
Medical Officer
Renowned neurologist and former chair of the FDA peripheral and central nervous system advisory Committee and former VP of the American Neurological Association. Iinvolved with every treatment approved by FDA in the last 20 years.
Brett Walker
Marketing Officer
Extensive experience leading product/service launches now producing over a billion dollars annually (Intel, Ancestry, Monster, VitalSmarts, Action Target). Market proficiency across multiple industries and all marketing disciplines.
Samantha John
Commercialization Officer
Formerly with Aimmune Therapeutics, UCB, and Eli Lilly. Brings deep expertise in global commercialization, brand strategy, and patient support across biotech and pharma. Proven success launching complex therapies in specialized markets.
Greg Schneider
Market Access Officer
Formerly with Medtronic, Pfizer, Siemens, Wyeth, Extensive drug and device market access expertise with deep experience in Medicare, VA and private coverage, coding, and payments.
Suzanne Hendrix, PhD
Biostatistican
Brad Wyman, PhD
SVP, Science
Mike Drake
VP Quality & Regulatory
Advisory Boards
Clinical & Scientific Advisory Board (CSAB)
Our Clinical & Scientific Advisory Board (CSAB) is comprised of leading experts in Parkinson’s disease (PD) and other neurodegenerative diseases. The board’s aim is to provide clinical and scientific advice and direction to support the PhotoPharmics mission to improve the lives of people who suffer from neurodegenerative diseases. Our leadership in non-invasive photo-neuromodulation for neurodegenerative diseases benefits from the advice and insight of this world-class advisory board.
Robert A. Hauser, MD, MBA, FAAN, Chair
Ray Chaudhuri, MD
Joohi Jimenez-Shahed, MD
Dan Claassen, MD, MS
Rajesh Pahwa, MD, FAAN
Amy Amara, MD, PhD
George C. Brainard, M.A., Ph.D.
Charles H. Adler, M.D., Ph.D
In Memoriam
Warren Olanow, MD (1941-2024)
Distinguished Physician, Researcher, Colleague, Father, and Friend
The entire PhotoPharmics team mourns the passing of Dr. C. Warren Olanow, a pivotal figure in neurology and chairman of our Clinical and Scientific Advisory Board. Dr. Olanow’s groundbreaking work in Parkinson’s and neurodegenerative research has profoundly advanced our understanding and treatment of movement disorders. His legacy will forever inspire our mission. We extend our heartfelt condolences to his family and honor his lifelong dedication to improving patient lives.
The world is less rich in his absence.
Commercial Advisory Board (CAB)
The Commercial Advisory Board (CAB) brings together accomplished experts in neurology, movement disorders, and the business of bringing new therapies to market. Its role is to advise PhotoPharmics on commercialization strategy, including pricing, access, and adoption, as Celeste® moves toward FDA review and approval. By drawing on this collective experience, PhotoPharmics strengthens its ability to transform photo-neuromodulation from a clinical breakthrough into an accessible treatment option for people with neurodegenerative diseases.
Jordan Dubow, MD – Chair
Philip Cyr, MPH
Drew Falconer, MD, FAAN
Rajesh Pahwa, MD, FAAN
Robert A. Hauser, MD, MBA, FAAN
Jill Giordano Farmer, DO, MPH, FCPP, DipABLM
